Drugs / Amlodipine
Amlodipine
also known as
Amlodipine Besylate · NorvasC · Aml · amlodipine besilate · HGP0904 · amlodipine camsylate · ALD · Amlo · +46 more
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Dafiro | — | 2007-01-15 | europa.eu ↗ |
| Label expansions (4) | US (FDA) | NORVASC | — | 1996-06-14 – 2005-09-28 | fda.gov ↗ |
| Approved | US (FDA) | NORVASC | — | 1992-07-31 | fda.gov ↗ |
Trials 352 · started per year
today
US approved 1992
EU approved 2007
1
1
1
1
1
1
4
1
10
20
13
22
25
25
14
18
14
9
13
26
17
16
13
13
11
10
10
17
4
8
6
5
198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07291375 | Dec 2025 → Jun 2026 overdue | — | Minia University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT02744456 | Aug 2014 → Aug 2017 | hypertensive disorder | Columbia University | Completed | No outcome recorded |
| Phase 185 trials · 7 met primary | ||||||
| Phase 1 | NCT07075965 | Dec 2026 → Oct 2030 expected | myotonic dystrophy type 1 | University of Rochester | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06012487 | May → Dec 2026 expected | — | Cedars-Sinai Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05808725 | Dec 2022 → Apr 2023 | coronary artery disorder, hypertensive disorder | Brillian Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05688085 | Oct → Dec 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05688098 | Sep → Nov 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05663073 | Sep → Dec 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05259020 | Feb → Mar 2022 | hyperlipidemia, hypertensive disorder | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05077475 | Sep 2021 → Apr 2022 | hypertensive disorder | AJU Pharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05077462 | Sep 2021 → Apr 2022 | hypertensive disorder | AJU Pharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04611932 | Nov 2020 → Mar 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04627207 | Nov 2020 → Mar 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04185090 | Feb → Apr 2020 | hyperlipidemia, hypertensive disorder | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04262765 | Feb → Mar 2019 | — | Midas Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04245046 | Jan → Feb 2019 | — | Midas Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04322266 | Dec 2018 → Feb 2019 | — | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 1 | NCT03707899 | Dec 2018 → Feb 2019 | hyperlipidemia, combined, 2 | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03662620 | Oct → Dec 2018 | hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03629067 | Sep → Nov 2018 | — | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03657550 | May → Sep 2018 | hypertensive disorder | Conjupro Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04081844 | May → Jun 2018 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03247140 | Jun → Aug 2017 | hyperlipidemia, combined, 2 | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03461081 | May → Jul 2017 | hyperlipidemia, combined, 2 | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03116516 | Apr → May 2017 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03032315 | Oct → Dec 2016 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02920047 | Oct 2016 → Jan 2017 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02995720 | Aug → Nov 2016 | hyperlipidemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02951962 | Aug → Sep 2016 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02814500 | Jul → Sep 2016 | — | Alvogen Korea | Unknown | No outcome recorded |
| Phase 1 | NCT02789475 | May → Jul 2016 | hyperlipidemia, hypertensive disorder | Alvogen Korea | Unknown | No outcome recorded |
| Phase 1 | NCT02739672 | Jan → Apr 2016 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02665832 | Jan → Jun 2016 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT02933658 | Nov 2015 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02569814 | Sep → Dec 2015 | hyperlipidemia, hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02548286 | Aug 2015 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02397538 | Feb → Apr 2015 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02243319 | Sep → Dec 2014 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02387554 | Aug → Oct 2014 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02233218 | Jul → Oct 2014 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02205151 | Jul → Sep 2014 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02064621 | Jun → Aug 2014 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02152969 | May → Aug 2014 | hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02064556 | May → Jul 2014 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02955498 | Apr → May 2014 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02075619 | Mar → Jul 2014 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02060019 | Mar → Jun 2014 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02069821 | Mar 2014 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03889145 | Dec 2013 → Feb 2014 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02058472 | Dec 2013 → May 2014 | — | Dong-A Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01926652 | Jul → Aug 2013 | — | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01822639 | Apr → May 2013 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01841593 | Apr → Sep 2013 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT01845272 | Apr → Jul 2013 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT01735890 | Sep → Nov 2012 | — | HK inno.N Corporation | Completed | Met primary |
| Phase 1 | NCT01648231 | Aug → Sep 2012 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01776047 | Jul → Sep 2012 | — | Dong-A Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01823913 | Jul → Aug 2012 | — | Severance Hospital | Completed | Met primary |
| Phase 1 | NCT01549496 | May → Sep 2012 | hepatitis C virus infection, hypertensive disorder | Ottawa Hospital Research Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT02295046 | Oct 2011 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02292069 | Sep 2011 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02962258 | May → Jun 2011 | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT01341392 | Apr → Aug 2011 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01198249 | Sep 2010 → Feb 2011 | essential hypertension | Yonsei University | Completed | No outcome recorded |
| Phase 1 | NCT01181011 | Aug → Nov 2010 | — | Boehringer Ingelheim | Completed | Met primary |
| Phase 1 | NCT01130168 | May → Nov 2010 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 1 | NCT01138826 | May → Jun 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01117038 | Apr → May 2010 | erectile dysfunction | VIVUS LLC | Completed | No outcome recorded |
| Phase 1 | NCT02261064 | Dec 2008 → Feb 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00789321 | Jul 2008 → Feb 2009 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 1 | NCT03912285 | Jan 2008 → Mar 2009 | — | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02259803 | Oct → Nov 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259777 | Sep → Nov 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259790 | Jul → Aug 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02194309 | Sep → Dec 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259816 | May → Aug 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00870571 | Apr → May 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00870142 | Apr → May 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00649402 | May → Jun 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649519 | May 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00834977 | Apr → May 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00835367 | Mar 2004 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00841815 | Apr → May 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00841542 | Apr → May 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00932880 | — | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT00039975 | ? → Apr 2004 | HIV infectious disease, hypertensive disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00932763 | — | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00156403 | Aug → Dec 2005 | pancreatitis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 220 trials · 3 met primary · 1 missed | ||||||
| Phase 2 | NCT06942377 | Jul 2025 → Jan 2027 expected | endometrial carcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05331144 | Oct 2022 → Jun 2027 expected | hereditary dementia, hypertensive disorder, subjective cognitive decline | Rong Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT05370599 | Apr 2022 → Jan 2026 | hypertensive disorder | University of California, San Francisco | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT06212648 | Mar → Nov 2022 | essential hypertension | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04954196 | Oct 2021 → Oct 2023 | — | University Hospital, Montpellier | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04692467 | Feb 2021 → Jun 2023 | HIV infectious disease | Weill Medical College of Cornell University | Completed | Met primary |
| Phase 2 | NCT04179019 | Sep 2020 → Dec 2023 | primary aldosteronism | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04488978 | May 2020 → Nov 2021 | essential hypertension | Handok Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03640312 | Aug 2019 → May 2022 | hypertensive disorder | Washington University School of Medicine | Completed | Missed primary |
| Phase 2 | NCT03024476 | Sep 2016 → Dec 2017 | hypertensive disorder, ischemic stroke | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02278471 | Dec 2015 → Jun 2018 | hyperlipidemia, hypertensive disorder | Vanderbilt University | Completed | Met primary |
| Phase 2 | NCT02944734 | Sep 2014 → Dec 2015 | essential hypertension | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02206165 | Mar 2014 → Apr 2015 | essential hypertension | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 2 | NCT02059616 | Feb 2014 → Jun 2015 | essential hypertension | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT01518998 | Aug 2011 → Oct 2013 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | Met primary |
| Phase 2 | NCT01264692 | Feb 2011 → Jan 2012 | essential hypertension | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00942344 | May → Dec 2007 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | Mixed |
| Phase 2 | NCT00015457 | Apr 2001 → Apr 2009 | focal dystonia | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00151619 | Feb 1999 → Sep 2001 | heart failure | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00000522 | Aug 1985 → May 1994 | heart disorder, hypertensive disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 2/311 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT06424834 | Oct 2024 → Dec 2026 expected | coronary artery intramyocardial course, coronary microvascular disorder, coronary vasospasm, intermediate coronary syndrome | Stanford University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02913664 | Feb 2017 → Nov 2021 | hypertensive disorder, subjective cognitive decline | University of Texas Southwestern Medical Center | Completed | Missed primary |
| Phase 2/3 | NCT02065492 | Feb 2014 → Oct 2015 | thalassemia | Aga Khan University | Completed | No outcome recorded |
| Phase 2/3 | NCT02408172 | Oct 2013 → Jun 2017 | hypertensive disorder, obstructive sleep apnea syndrome | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01956786 | Sep → Dec 2013 | essential hypertension | Shenzhen Ausa Pharmed Co.,Ltd | Unknown | Met primary |
| Phase 2/3 | NCT01848873 | Jan → Aug 2013 | essential hypertension | Shenzhen Ausa Pharmed Co.,Ltd | Unknown | No outcome recorded |
| Phase 2/3 | NCT01255475 | Jan 2011 → Oct 2012 | congestive heart failure | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT01280266 | Jan → May 2011 | Raynaud disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT04740840 | May 2010 → Apr 2012 | hypertensive disorder | Affiliated Hospital of North Sichuan Medical College | Completed | No outcome recorded |
| Phase 2/3 | NCT01125254 | Sep 2008 → Jul 2011 | beta-thalassemia major | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 2/3 | NCT00425373 | Nov 2006 → Mar 2008 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3103 trials · 36 met primary · 2 missed | ||||||
| Phase 3 | NCT07618806 | Nov 2026 → Dec 2027 expected | hypertensive disorder | Zentiva, k.s. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07704697 | Nov 2024 → Nov 2025 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06348576 | May 2024 → Feb 2025 | essential hypertension | Addpharma Inc. | Unknown | Met primary |
| Phase 3 | NCT06236061 | Apr 2024 → May 2025 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT06052748 | Feb 2024 → Mar 2025 | essential hypertension | Addpharma Inc. | Completed | Met primary |
| Phase 3 | NCT07704684 | Jun 2023 → Aug 2025 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT07564726 | Aug 2022 → Feb 2024 | essential hypertension, hyperlipoproteinemia | Celltrion Pharm, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05475665 | Jul 2022 → Mar 2023 | essential hypertension | Handok Inc. | Completed | Met primary |
| Phase 3 | NCT05476354 | Jul 2022 → Apr 2023 | essential hypertension | Handok Inc. | Completed | Met primary |
| Phase 3 | NCT05155137 | Dec 2021 → Dec 2029 expected | cognitive disorder, stroke disorder | Hospital Moinhos de Vento | Recruiting | No outcome recorded |
| Phase 3 | NCT04518293 | Jul 2021 → Aug 2023 | hypertensive disorder | George Medicines PTY Limited | Completed | Met primary |
| Phase 3 | NCT04518306 | Jun 2021 → Sep 2023 | hypertensive disorder | George Medicines PTY Limited | Completed | Met primary |
| Phase 3 | NCT03785067 | Feb 2020 → Feb 2021 | hypertensive disorder, intracerebral hemorrhage, vascular dementia | The George Institute | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04161001 | Nov 2019 → Nov 2021 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT03991442 | Jun 2019 → Mar 2021 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05820880 | May 2019 → Feb 2022 | essential hypertension | Servier | Completed | No outcome recorded |
| Phase 3 | NCT02699645 | Sep 2017 → Aug 2025 | hypertensive disorder, intracerebral hemorrhage | The George Institute | Completed | Met primary |
| Phase 3 | NCT03103256 | May 2017 → Apr 2018 | hyperlipidemia | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02969265 | May 2017 → Jul 2018 | hypertensive disorder | Takeda | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03067688 | Apr 2017 → Mar 2018 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | Met primary |
| Phase 3 | NCT03009487 | Jan 2017 → Apr 2018 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT02979197 | Nov 2016 → Jul 2017 | hypertensive disorder | Kitov Pharma Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03210532 | Oct 2016 → Sep 2017 | hyperlipidemia, hypertensive disorder | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03088254 | Sep 2016 → Jul 2017 | — | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03566316 | Nov 2015 → Jun 2017 | hyperlipidemia, combined, 2 | IlDong Pharmaceutical Co Ltd | Completed | Met primary |
| Phase 3 | NCT02651870 | Apr 2015 → Feb 2016 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT02368665 | Dec 2014 → Nov 2015 | essential hypertension | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02368652 | Dec 2014 → Nov 2015 | essential hypertension | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02277691 | Nov 2014 → Apr 2016 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT04952051 | Jul 2014 → Jul 2019 | hypertensive disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| Phase 3 | NCT02899455 | Jul 2014 → Jun 2016 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 3 | NCT02172040 | Jun 2014 → Nov 2015 | hypertensive disorder | Kitov Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02152306 | Apr 2014 → Mar 2015 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | Met primary |
| Phase 3 | NCT01865188 | Apr 2014 → Apr 2015 | essential hypertension | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01977794 | Mar 2014 → Mar 2015 | essential hypertension | Merck KGaA, Darmstadt, Germany | Completed | Met primary |
| Phase 3 | NCT01911780 | Jul 2013 → Jan 2015 | essential hypertension | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT01838850 | Apr 2013 → Aug 2014 | essential hypertension | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT01395199 | Aug 2012 → Feb 2015 | beta-thalassemia major, disorder of iron metabolism and transport | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 3 | NCT01625494 | May 2012 → Jan 2013 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01557153 | Apr 2012 → Apr 2014 | depressive disorder | Gateshead Health NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 3 | NCT01613209 | Dec 2011 → Sep 2012 | hypertensive disorder | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01299376 | Jan → Nov 2011 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01259297 | Jan 2011 → Nov 2012 | — | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 3 | NCT01237873 | Jan 2011 → Feb 2012 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01204398 | Nov 2010 → Jul 2011 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01222520 | Oct 2010 → Jun 2011 | essential hypertension | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT01113047 | May → Oct 2010 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01134393 | May 2010 → May 2011 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01001572 | Sep 2009 → May 2010 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00957554 | Jul 2009 → Sep 2010 | hypertensive disorder | Sanofi | Completed | Met primary |
| Phase 3 | NCT00956644 | Jul 2009 → Aug 2010 | essential hypertension | Sanofi | Completed | Met primary |
| Phase 3 | NCT00923091 | Jun 2009 → Jan 2011 | essential hypertension | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT01127217 | May 2009 → Mar 2010 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 3 | NCT00867490 | Mar → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00797862 | Nov 2008 → Nov 2010 | essential hypertension | Novartis | Completed | Mixed |
| Phase 3 | NCT00778921 | Oct 2008 → Jun 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00777946 | Oct 2008 → May 2009 | essential hypertension | Novartis | Completed | Met primary |
| Phase 3 | NCT00739973 | Sep 2008 → May 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00765674 | Sep 2008 → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00667719 | Jun 2008 → Oct 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00940667 | May → Dec 2008 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 3 | NCT00649389 | May 2008 → Apr 2009 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT00699192 | May 2008 → May 2009 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00940680 | Apr → Nov 2008 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 3 | NCT00624052 | Mar 2008 → Jun 2009 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00618774 | Jan 2008 → Oct 2009 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00614380 | Jan 2008 → Mar 2009 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00553267 | Nov 2007 → Oct 2008 | hypertensive disorder | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT00558428 | Oct 2007 → Sep 2008 | hypertensive disorder | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT00550953 | Oct 2007 → Jul 2008 | essential hypertension | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT00558064 | Oct 2007 → Sep 2008 | hypertensive disorder | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT00527514 | Sep 2007 → Apr 2008 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT00548067 | Sep 2007 → Mar 2008 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00523744 | Jul → Dec 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00443456 | May 2007 → Jun 2008 | hypertensive disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00446563 | Mar 2007 → Mar 2010 | hypertensive heart disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00446524 | Feb 2007 → Oct 2008 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00413413 | Jan → Nov 2007 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00415623 | Jan → Oct 2007 | hypertensive disorder | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00437645 | Jan → Nov 2007 | essential hypertension | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00402103 | Nov 2006 → Apr 2008 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00392262 | Aug 2006 → Feb 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00350168 | Jun 2006 → Apr 2007 | hypertensive disorder | Novartis | Completed | Met primary |
| Phase 3 | NCT00353912 | Jun 2006 → Apr 2007 | hypertensive disorder | Novartis | Completed | Met primary |
| Phase 3 | NCT00327587 | May 2006 → Aug 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00281580 | Apr 2006 → Mar 2007 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00327145 | Mar 2006 → Jan 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00289406 | Jan → Feb 2006 | hypertensive disorder | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00367939 | Dec 2005 → Jul 2006 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00185133 | May 2005 → Jan 2007 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00220220 | Apr 2005 → Apr 2007 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00171002 | Nov 2004 → Jun 2005 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00330785 | Oct 2004 → Sep 2005 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00170963 | Oct 2004 → Jun 2005 | hypertensive disorder | Novartis | Completed | Met primary |
| Phase 3 | NCT00171535 | Oct 2004 → Apr 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00171366 | Jul 2004 → Jul 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00170976 | Apr 2004 → Jun 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00409643 | Jan → Jul 2004 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00170950 | Oct 2003 → Jan 2008 | hypertensive disorder | Novartis | Terminated | Met primary |
| Phase 3 | NCT00409851 | Apr 2003 → Mar 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00409760 | Jan 2003 → Feb 2004 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT04364139 | Feb 1995 → Sep 2001 | chronic kidney disease, nephrosclerosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Mixed |
| Phase 3 | NCT00000542 | Aug 1993 → Mar 2002 | coronary artery disorder, diabetes mellitus, heart failure, hyperlipidemia +3 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 4110 trials · 10 met primary · 5 missed | ||||||
| Phase 4 | NCT07240909 | Jan → Dec 2026 expected | hypertensive disorder | The Third Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06730945 | Jun 2025 → Dec 2028 | — | Ruijin Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT04974138 | Aug 2024 → Jun 2030 expected | hyperhomocysteinemia, hypertensive disorder | Shenzhen Ausa Pharmed Co.,Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT04974151 | Aug 2024 → Jun 2029 expected | hyperhomocysteinemia, hypertensive disorder | Shenzhen Ausa Pharmed Co.,Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT05917275 | Apr 2024 → Oct 2025 | essential hypertension | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT06275763 | Oct 2023 → Dec 2025 | hypertensive disorder | National Institute of Cardiology, Warsaw, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT06487949 | Dec 2022 → Oct 2023 | hypertensive disorder | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT05683301 | Aug 2022 → Aug 2024 | essential hypertension | Centre for Chronic Disease Control, India | Completed | No outcome recorded |
| Phase 4 | NCT05377203 | Jul 2022 → Jul 2023 | hypertensive disorder | The Third Xiangya Hospital of Central South University | Completed | Met primary |
| Phase 4 | NCT04840342 | Feb 2022 → Sep 2025 | apparent mineralocorticoid excess, essential hypertension | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05155436 | Jan 2022 → Mar 2023 | hypertensive disorder, mineral metabolism disease | National Heart Foundation of Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT05165251 | Jan 2022 → Dec 2024 | — | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT04790279 | Apr 2021 → Dec 2022 | hypertension, pregnancy-induced | Prisma Health-Upstate | Completed | No outcome recorded |
| Phase 4 | NCT05089448 | Jan 2021 → Jun 2026 overdue | hypertensive disorder, substance abuse | Yan Li | Recruiting | No outcome recorded |
| Phase 4 | NCT04559074 | Oct 2020 → Nov 2021 | hypertensive disorder | Queen Mary University of London | Completed | No outcome recorded |
| Phase 4 | NCT06713785 | Sep 2020 → Jan 2021 | essential hypertension | Queen Mary University of London | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04111419 | Jul 2020 → Sep 2026 overdue | atrial fibrillation, hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04330300 | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT04085562 | Sep 2019 → Feb 2021 | renal hypertension | Alexandria University | Completed | Met primary |
| Phase 4 | NCT03978884 | Jun 2019 → May 2020 | diabetes mellitus, hypertensive disorder | The University of The West Indies | Withdrawn | No outcome recorded |
| Phase 4 | NCT03951207 | May 2019 → Sep 2021 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | Met primary |
| Phase 4 | NCT03667677 | Feb 2019 → Feb 2020 | anxiety, hypertensive disorder | Chongqing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03683069 | Jan 2019 → Aug 2023 | essential hypertension, genetic | Brigham and Women's Hospital | Completed | Mixed |
| Phase 4 | NCT03666351 | Oct 2018 → Jul 2022 | aortic valve insufficiency, aortic valve stenosis, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 4 | NCT03626259 | Aug 2018 → Jan 2019 | hypertensive disorder | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT03682692 | Jun 2018 → Jun 2021 | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Completed | Missed primary |
| Phase 4 | NCT03474562 | Apr 2018 → Jun 2019 | atherosclerotic cardiovascular disease, hypertensive disorder, prediabetes syndrome | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03461003 | Apr 2018 → Nov 2020 | early onset hypertension | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03738761 | Feb 2018 → Sep 2019 | essential hypertension | KRKA | Completed | No outcome recorded |
| Phase 4 | NCT03319823 | Oct 2017 → Feb 2019 | hypertensive disorder | Cedars-Sinai Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT04521023 | Sep 2017 → Jan 2020 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT03294070 | Sep 2017 → Mar 2018 | hypertensive disorder | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT03231982 | Apr 2017 → Apr 2019 | essential hypertension | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT02973035 | Dec 2016 → Jan 2020 | hypertensive disorder | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02847338 | Nov 2016 → Oct 2023 | hypertensive disorder | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT03747978 | Oct 2016 → May 2017 | hypertensive disorder, type 2 diabetes mellitus | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05467384 | Mar 2016 → Jun 2017 | hyperlipidemia, hypertensive disorder | Ayub Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT04474899 | Jun 2015 → Feb 2024 | hypertensive disorder, obesity disorder | Royal Perth Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02378064 | May 2015 → Dec 2017 | atherosclerosis, coronary artery disorder | CHEOL WHAN LEE, M.D., Ph.D | Completed | Missed primary |
| Phase 4 | NCT01922141 | May 2015 → Jun 2018 | hypertensive disorder | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT02433119 | Mar 2015 → Sep 2016 | hypertensive disorder | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02377661 | Mar 2015 → May 2017 | hypertensive disorder | Wilhelminenspital Vienna | Completed | Met primary |
| Phase 4 | NCT02353806 | Jan 2015 → Jul 2016 | hypertension, pregnancy-induced | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02062645 | Feb 2014 → Sep 2015 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02058446 | Oct 2013 → Mar 2014 | essential hypertension | TSH Biopharm Corporation Limited | Completed | No outcome recorded |
| Phase 4 | NCT01120327 | Sep 2011 → Dec 2014 | coronary artery disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01180413 | Dec 2010 → Apr 2012 | essential hypertension | Aarhus University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01198496 | Oct 2010 → Dec 2017 | essential hypertension, stroke disorder | Biomedis International Ltd. | Unknown | Missed primary |
| Phase 4 | NCT01030458 | Sep 2010 → Mar 2012 | hypertensive disorder | KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01828359 | Aug 2010 → Jan 2013 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT01190007 | Aug 2010 → Feb 2012 | hyperlipoproteinemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01167153 | May 2010 → Apr 2011 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01713920 | Apr 2010 → Sep 2014 | hypertensive disorder | Sang Hyun Ihm, MD PhD | Completed | No outcome recorded |
| Phase 4 | NCT01070030 | Jan → Oct 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01048047 | Nov → Dec 2009 | hypertensive disorder | University of Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT01030081 | Oct 2009 → Mar 2013 | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01394770 | Sep 2009 → Sep 2012 | hypertensive disorder | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT00931710 | Jul 2009 → Jan 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00902304 | Jul 2009 → Jul 2011 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01070043 | Jun 2009 → Sep 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00942994 | Jun 2009 → Mar 2010 | hypertensive disorder | Novartis | Completed | Met primary |
| Phase 4 | NCT01241487 | Feb 2009 → Jan 2011 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00819104 | Nov 2008 → Aug 2009 | essential hypertension | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00791258 | Nov 2008 → Aug 2009 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00765947 | Sep 2008 → Aug 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00654745 | May 2008 → Apr 2009 | essential hypertension, type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT01091753 | Mar 2008 → May 2009 | hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00538486 | Feb 2008 → Jun 2009 | hypertensive disorder, obesity disorder | Third Military Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01738945 | Feb 2008 → May 2009 | — | Gulhane School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00921570 | Feb 2008 → May 2009 | hypertensive disorder, proteinuria, type 2 diabetes mellitus | Gulhane School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00700271 | Oct 2007 → Aug 2008 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00492128 | Sep 2007 → May 2009 | hypertensive disorder | Yokohama City University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01830517 | Aug 2007 → Jun 2011 | hypertensive disorder, ischemic stroke | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT00509470 | Jul 2007 → Jun 2012 | essential hypertension | Tokyo University | Completed | No outcome recorded |
| Phase 4 | NCT01375322 | Jun 2007 → Jun 2010 | hypertensive disorder, proteinuria, type 2 diabetes mellitus | TSH Biopharm Corporation Limited | Completed | Met primary |
| Phase 4 | NCT00407537 | Mar 2007 → Oct 2009 | hyperlipoproteinemia, hypertensive disorder | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00460915 | Jan 2007 → Jul 2009 | hypertensive disorder | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00412113 | Jan 2007 → Apr 2008 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00425997 | Dec 2006 → Oct 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00523549 | Nov 2006 → Jan 2008 | hypertensive disorder | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 4 | NCT00426478 | Nov 2006 → Sep 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00890591 | Aug 2006 → Jun 2007 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00400777 | Aug 2006 → Nov 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00351130 | Jun 2006 → Mar 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00313547 | Apr 2006 → Apr 2007 | hypertensive disorder | Montreal Heart Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00311155 | Mar 2006 → Apr 2008 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 4 | NCT00304226 | Feb 2006 → Jan 2007 | hypertensive disorder | Novartis | Completed | Met primary |
| Phase 4 | NCT00338338 | Nov 2005 → Sep 2007 | essential hypertension | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00242814 | Nov 2005 → Mar 2007 | hypertensive disorder, metabolic syndrome X | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00185120 | Sep 2005 → Sep 2006 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00174330 | May 2005 → Feb 2006 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00136851 | Dec 2004 → Jul 2005 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00741078 | Dec 2004 → Aug 2008 | hypertensive disorder | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00237588 | Dec 2004 → Jul 2005 | hypertensive disorder | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00174304 | Oct 2004 → Sep 2006 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00144144 | Sep 2004 → Sep 2008 | hypertensive disorder, type 2 diabetes mellitus | Advanced-J | Unknown | No outcome recorded |
| Phase 4 | NCT00150384 | Jul 2004 → Aug 2005 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00139555 | Jul 2004 → Nov 2006 | hypertensive disorder, hypertensive heart disease | Novartis | Completed | Missed primary |
| Phase 4 | NCT07436104 | Jan 2004 → Dec 2015 | asthma, chronic diarrheal disease, chronic obstructive pulmonary disease, hypertensive disorder +2 | MAHAN Trust | Completed | No outcome recorded |
| Phase 4 | NCT00202618 | Dec 2003 → Jun 2006 | diabetes mellitus, hypertensive disorder, proteinuria | Shiga University | Unknown | No outcome recorded |
| Phase 4 | NCT00171054 | Sep 2003 → Oct 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00136773 | Apr 2003 → Oct 2005 | proteinuria | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00159692 | Mar 2003 → Aug 2005 | hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00240474 | Dec 2002 → Mar 2004 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00367978 | Dec 2001 → Sep 2003 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00159718 | Jul 2001 → Jan 2007 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00143195 | Apr 2001 → Jan 2005 | myocardial ischemia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00140985 | Feb 2000 → Jan 2002 | kidney disorder | Organon and Co | Completed | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT07679828 | Jul 2026 → Dec 2029 expected | hyperlipidemia, hypertensive disorder, type 2 diabetes mellitus | China Medical University, China | Recruiting | No outcome recorded |
| — | NCT07099677 | Aug 2025 → Jun 2026 overdue | essential hypertension | Abant Izzet Baysal University | Recruiting | No outcome recorded |
| — | NCT06790927 | Feb 2025 → Dec 2026 expected | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT06780865 | Jan 2025 → Dec 2028 expected | chronic kidney disease, secondary hypertension | Shanghai Institute of Hypertension | Not yet recruiting | No outcome recorded |
| — | NCT05976438 | Aug 2023 → Dec 2024 | hypertensive disorder | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT07259733 | Jul 2023 → Dec 2026 expected | resistant hypertension | Instituto Dante Pazzanese de Cardiologia | Recruiting | No outcome recorded |
| — | NCT04521582 | Apr 2021 → Apr 2022 | essential hypertension | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| — | NCT03783754 | Aug 2018 → Mar 2021 | hypertensive disorder, intracerebral hemorrhage, vascular dementia | The George Institute | Terminated | No outcome recorded |
| — | NCT02474420 | Jun 2015 → Jun 2017 | beta thalassemia, disorder of iron metabolism and transport | Kevin H.M. Kuo, MD, MSc, FRCPC | Unknown | No outcome recorded |
| — | NCT02671695 | Apr 2015 → Apr 2018 | beta-thalassemia major | Tanta University | Completed | No outcome recorded |
| — | NCT02544776 | Jan → Aug 2015 | anovulation | Ahmed Fathy Ali Mohamed Ghanem | Completed | No outcome recorded |
| — | NCT01835418 | Apr 2013 → Jul 2014 | hypertensive disorder | Allina Health System | Unknown | No outcome recorded |
| — | NCT01658657 | Oct 2012 → Jul 2014 | hypertensive disorder, proteolytic capacity of plasma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT01354613 | Apr 2011 → Dec 2013 | diastolic heart failure, hypertensive heart disease, lung disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00693199 | Jul → Oct 2006 | hypertensive disorder | Anhui Medical University | Completed | No outcome recorded |
| — | NCT00337298 | Jul 2006 → Feb 2009 | diabetic retinopathy, type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT00834600 | Dec 2005 → Oct 2011 | hypertensive disorder | The Louis & Rachel Rudin Foundation | Completed | No outcome recorded |
| — | NCT00656331 | Aug 2005 → Jun 2012 | hypertensive disorder | University of New Mexico | Withdrawn | No outcome recorded |
| — | NCT00518479 | Sep 2003 → Apr 2004 | hypertensive disorder, hypertensive heart disease | University of Leeds | Completed | No outcome recorded |
| — | NCT00382421 | Feb 1992 → Apr 2006 | myocardial ischemia | Luzerner Kantonsspital | Completed | No outcome recorded |
| Comparator or background therapy198 trials | ||||||
| Phase 0 | NCT06796660 Background | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05667818 Comparator | Jan → Feb 2023 | hypertensive disorder | Overseas Pharmaceuticals, Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04329806 Comparator | Feb 2021 → Jul 2022 | abdominal obesity-metabolic syndrome | Italo Biaggioni | Terminated | No outcome recorded |
| Phase 1 | NCT04667624 Comparator | Feb → Apr 2020 | hypertensive disorder | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02608242 Comparator | Nov 2015 → Jun 2016 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Terminated | No outcome recorded Stop: Business |
| Show all 198 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 45
| Date | Issuer | Release |
|---|---|---|
| 2026-09-22 | Hanmi Pharmaceutical Company Limited | Results 한미약품 “‘ 아모잘탄’ 성분 기반 병용요법 임상적 가치 주목” hanmi.co.kr ↗
또한 로사르탄을 포함한 모든 ARB/암로디핀 병용요법군에서 복용 중단군 대비 주요 심혈관 사건 발생 위험을 유의하게 낮췄으며, ARB간의 차이는 크지 않은 것으로 나타났다. |
| 2026-06-01 | Chong Kun Dang Pharmaceutical | Results 종근당, 유럽고혈압학회서 '텔미누보 20/1.25mg' 3상 임상 결과 발표 ckdpharm.com ↗
암로디핀 5mg 단일제(-13.90mmHg)와의 비교에서도 우월한 효과를 확인했다. |
| 2025-06-13 | Hanmi Pharmaceutical Company Limited | Regulatory “고혈압 1차 치료의 새로운 길”…한미약품 ‘아모프렐’ 출격 준비 hanmi.co.kr ↗
한미약품은 최근 식품의약품안전처로부터 저용량 3제 항고혈압제 ‘아모프렐정’의 품목허가를 획득하고 출시를 위한 채비에 들어갔다고 13일 밝혔다. |
| 2024-09-20 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - VALSARTAN LEVOAMLODIPINE MALEATE TABLETS OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
VALSARTAN LEVOAMLODIPINE MALEATE TABLETS OBTAINS CLINICAL TRIAL APPROVAL |
| 2023-05-31 | Tavanta Therapeutics | Results Tavanta Therapeutics to Showcase Specialty Pipeline During the 2023 American Society of Clinical Oncology (ASCO) and American Society of Colon and Rectal Surgeons (ASCRS) Annual Congresses tavanta.com ↗
TAVT-119 (amlodipine besylate) Gel: Results from Phase 2 Study Demonstrate that Topical TAVT-119 Treatment was Well Tolerated and Showed Promise in Reducing Pain in Patients with Anal Fissure |
| 2021-07-09 | Midas Pharma GmbH | Regulatory Value Added Medicines – A key for differentiation and success in the pharmaceutical world midas-pharma.com ↗
In cooperation with one of our development partners Midas was able to get approval for the first new fixed dose combination product including three active pharmaceutical ingredients (Ramipril+Amlodipine+HCTZ) within the EU. |
| 2019-11-14 | Hanmi Pharmaceutical Company Limited | Results <보도자료> “아모잘탄패밀리, 고혈압치료 병용시 우선적 권고 근거 충분” hanmi.co.kr ↗
대한고혈압학회에서 주관했던 The K-Central study는 병용 요법에 있어 CCB와 ARB의 조합인 아모잘탄이 ARB와 이뇨제의 병용 요법보다 우수한 중심혈압 및 활동혈압 조절 효과를 증명했다 |
| 2019-09-18 | Hanmi Pharmaceutical Company Limited | Results <보도자료> '아모잘탄 우수성 글로벌 입증'...SCI급 국제학술지에 11번째 등재 hanmi.co.kr ↗
연구 결과에 따르면, 투여 20주 후 경동맥-대퇴동맥의 맥파전달속도(ambulatory carotid femoral Pulse Wave Velocity, 이하 맥파전달속도) 변화량이 아모잘탄 투여군에서 유의하게 감소하는 결과를 보였다. |
| 2019-05-31 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 발매 10주년 맞은 아모잘탄, 국제학술지 10번째 등재 hanmi.co.kr ↗
특히, 투여 20주 후의 24시간 실시간 중심ㆍ활동혈압 변화는 아모잘탄 투여군(각각 -9.4, -10.1mmHg)이 ARB/HCTZ 투여군(각각 -6.3, -6.7mmHg)보다 통계적으로 우월한 것으로 나타났다. |
| 2019-05-22 | Hanmi Pharmaceutical Company Limited | Results <보도자료> “고혈압치료의 모범답안”...아모잘탄패밀리 1알에 담겼다 hanmi.co.kr ↗
김 교수는 “고혈압 환자들의 목표혈압 도달을 위해서는 2제 이상의 항고혈압제가 필요한데, 아모잘탄은 ARB/HCTZ 2제 병용요법 대비 비열등한 강압 효과를 보여준 동시에 요산 감소 효과를 기대할 수 있다”고 말했다. |
| 2019-03-11 | Jeil Pharmaceutical Co., Ltd. | Results 제일약품 "텔미듀오플러스"3제 복합제 임상 3상 결과 SCI급 국제학술지 게재 jeilpharm.co.kr ↗
연구 결과 , 텔미사탄 / 암로디핀 / 로수바스타틴 투여군의 msSBP 는 베이스라인 대비 8 주 시점에서 24mmHg 감소 , 대조군 2 대비 15.mmHg ([95% CI, -21.78 to -8.43mmHg], P<0.001) 감소 효과를 보이며 고혈압 조절 효과의 탁월함을 입증했다 . |
| 2019-03-04 | Daewoong Pharmaceutical Co. LTD. | Regulatory Daewoong Pharmaceutical has completed the lineup of hypertension medications with the approval of ‘Olomax.’ daewoong.co.kr ↗
Daewoong Pharmaceutical (CEO Sengho Jeon) announced last 27th that KFDA has approved ‘Olomax,’ the compound of Amlodipine added to ‘Olostar,’ the existing compound of Olmesartan and Rosuvastatin. |
| 2018-06-12 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품, 아모잘탄·로벨리토 임상 결과 유럽고혈압학회 발표 hanmi.co.kr ↗
연구결과, 아모잘탄 투여군에서 ARB/hydrochlorothiazide 복합제 투여군 대비, 24시간 활동혈압 중 수축기 혈압의 조절 효과가 우수하게 나타났으며, 야간의 수축기 중심혈압과 맥파전달속도(PWV, Pulse Wave Velocity), 평탄지수(SI, Smoothness Index)와 같은 혈역학적 지수에 있어 우수한 조절 효과를 보였다. |
| 2018-05-23 | Hanmi Pharmaceutical Company Limited | Results <보도자료> “임상적 효과 입증한 아모잘탄 패밀리, 용량 선택도 다양” hanmi.co.kr ↗ |
| 2018-04-12 | Shin Poong Pharmaceutical Co. Ltd. | Results 칸데암로,에제로수 전국투어심포지움 shinpoong.co.kr ↗
칸데암로정은 우수한 목표혈압 달성률과 반응률을 나타냈고 , 단일제 대비 칸데암로정 고용량에서도 부작용이 경미해 , 고혈압치료에 있어서 주요제품으로 자리매김 할 것으로 기대했다 . |
| 2018-03-12 | Shin Poong Pharmaceutical Co. Ltd. | Results 칸데암로,에제로수 서울권 심포지엄 shinpoong.co.kr ↗
또한 SCI 급 국제학술지인 Clinical Therapeutics 에 등재된 칸데암로 2 상 임상결과를 소개하며 유효성과 안전성이 입증된 복합 제임을 강조했다 . |
| 2018-01-24 | Shin Poong Pharmaceutical Co. Ltd. | Results 항고혈압 복합제 개량신약 칸데암로정 전국투어Symposium개최 shinpoong.co.kr ↗
또한 SCI 급 국제학술지인 Clinical Therapeutics 에 등재된 칸데암로정 2 상 임상결과를 소개하며 유효성과 안정성을 제시했다 , |
| 2017-11-21 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품 ‘아모잘탄큐’ 3상 결과 SCI급 국제학술지 등재 hanmi.co.kr ↗
임상 결과, 아모잘탄큐 투여군은 Losartan/Rosuvastatin 투여군과 비교하여 투여 8주 후 SBP 기준 12mmHg 더 강력한 강압 효과를 나타냈으며, 투여 4주차 시점에서 약 96%의 우수한 혈압반응률을 보였다. |
| 2017-11-07 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품, 대한고혈압학회서 ‘아모잘탄 패밀리’ 심포지엄 hanmi.co.kr ↗ |
| 2017-10-19 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품 ‘아모잘탄플러스’ 3상 결과, SCI급 국제학술지 등재 hanmi.co.kr ↗
임상 결과, 아모잘탄플러스 투여군이 Amlodipine/Losartan 2제 요법 투여군과 비교하여 기저치 대비 8주 후 sitSBP를 평균 9.5mmHg 더 감소시키는 결과를 보였다. |
| 2017-10-13 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품, 대한심장학회서 ‘아모잘탄 패밀리’ 심포지엄 열어 hanmi.co.kr ↗ |
| 2017-07-24 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> “한미 1등 브랜드 아모잘탄, ‘패밀리’로 진용 갖췄다” hanmi.co.kr ↗
한미약품은 최근 혈압을 떨어뜨리는데 효과가 있는 이뇨제 성분 ‘클로르탈리돈’을 아모잘탄에 결합한 ‘아모잘탄플러스’와, 아모잘탄에 고지혈증치료 성분 ‘로수바스타틴’을 더한 ‘아모잘탄큐’의 시판허가를 각각 받았다. |
| 2017-07-17 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미, 고혈압+고지혈증 치료 3제 복합신약 허가 hanmi.co.kr ↗
한미약품(대표이사 우종수·권세창, www.hanmi.co.kr)이 2가지 고혈압치료 성분과 1가지 고지혈증 치료 성분을 합친 3제 복합신약 ‘아모잘탄큐’의 식약처 시판허가를 받았다고 17일 밝혔다. |
| 2017-06-30 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미, 고혈압치료 3제 복합신약 ‘아모잘탄플러스’ 허가 hanmi.co.kr ↗
한미약품(대표이사 우종수·권세창, www.hanmi.co.kr)은 지난 29일 고혈압치료 3제 복합신약인 ‘아모잘탄플러스’의 시판허가를 식품의약품안전처로부터 받았다고 30일 밝혔다. |
| 2016-11-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval of Generic Tribenzor® in the United States tevapharm.com ↗
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced approval of generic Tribenzor®1(olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the U.S. and is in the final stages of launch preparation. |
| 2016-09-28 | Astellas Pharma Inc | Regulatory Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination- astellas.com ↗
announced that manufacturing and marketing approval for “Micatrio® Combination Tablets,” a combination of “Micardis® Tablets” (AT1 receptor blocker [ARB]), long-acting calcium channel blocker (CCB) amlodipine besylate and the thiazide diuretic hydrochlorothiazide (HCTZ) was obtained on September 28. |
| 2016-03-17 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceuticals - Daiichi-Sankyo Korea Expect sales of 30 billion won this year with Sevikar HCT daewoong.co.kr ↗
Whereas a double combination drug of Amlodipine and Olmesartan Medoxomil were not effective, Sevikar HCT displayed significant reduction in both systolic and diastolic pressure. |
| 2015-09-23 | IlDong Pharmaceutical Co Ltd | Regulatory 항고혈압, 고지혈증 3제복합제 TAR정 임상 3상 착수 ildong.com ↗
일동제약(대표 이정치)이 항고혈압·고지혈 3제 복합제 TAR정(Telmisartan-Amlodipine-Rosuvastatin)에 대해 최근 식약처로부터 임상 3상을 승인받아, 이에 착수했다. |
| 2014-03-24 | Takeda | Regulatory Takeda Announces the New Drug Application Approval of Zacras ® Combination Tablets LD and Zacras ® Combination Tablets HD in Japan for the Treatment of Hypertension takeda.com ↗
Takeda Pharmaceutical Company Limited (“Takeda”) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application (NDA) of Zacras ® tablets, a fixed-dose combination ("FDC") of azilsartan* (generic name) and amlodipine besylate hydrochloride (generic name, "amlodipine"), for treatment of hypertension. |
| 2012-09-28 | Sumitomo Pharma America, Inc. | Regulatory Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for "AIMIX Combination Tablets LD/HD" sumitomo-pharma.com ↗ |
| 2012-06-22 | Sumitomo Pharma America, Inc. | Regulatory Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for long-acting calcium antagonist AMLODIN tablets/OD tablets for the Additional Indication of "Hypertension in pediatric patients" sumitomo-pharma.com ↗ |
| 2012-02-20 | Sumitomo Pharma America, Inc. | Regulatory Dainippon Sumitomo Pharma Submits Application Based on Public Knowledge for long-acting calcium antagonist AMLODIN tablets/OD tablets for the Additional Indication of "Hypertension in pediatric patients" sumitomo-pharma.com ↗
Therefore DSP was able to submit the application. |
| 2011-11-30 | Sumitomo Pharma America, Inc. | Regulatory Dainippon Sumitomo Pharma announces application for manufacturing and marketing approval for "DSP-8153", combination product of irbesartan and amlodipine besilate sumitomo-pharma.com ↗
it submitted an application for manufacturing and marketing approval for "DSP-8153" (product code) |
| 2011-07-04 | Daewoong Pharmaceutical Co. LTD. | Results Sevikar, antihypertensive agent, proved 24 hours long effect daewoong.co.kr ↗
As a result, it was found that Sevikar reached target BP for 24 hours (70.9%), and had an excellent BP reduction in systolic pressure compared with placebo at 21.4mmHg. |
| 2010-12-21 | Daiichi Sankyo | Regulatory Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure* daiichisankyo.com ↗
Daiichi Sankyo Europe announced today that Sevikar HCT® is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). |
| 2010-07-27 | Daiichi Sankyo | Regulatory FDA APPROVES TRIBENZOR™, A NEW THREE-IN-ONE COMBINATION PRODUCT FOR THE TREATMENT OF HIGH BLOOD PRESSURE daiichisankyo.com ↗
FDA APPROVES TRIBENZOR™, A NEW THREE-IN-ONE COMBINATION PRODUCT FOR THE TREATMENT OF HIGH BLOOD PRESSURE |
| 2009-09-11 | Sumitomo Pharma America, Inc. | Regulatory New OD tablet of AMLODIN by original formulation technology "SUITAB-NEX" sumitomo-pharma.com ↗
the Company has obtained an approval to modify part of the manufacture and sale conditions |
| 2008-11-13 | Daiichi Sankyo | Regulatory DAIICHI SANKYO EUROPE GmbH announce SEVIKAR® a new fixed dose combination treatment for essential hypertension daiichisankyo.com ↗
GERMANY, the European headquarter of DAIICHI SANKYO, is the latest country in Europe to grant marketing approval for SEVIKAR® |
| 2007-09-28 | Daiichi Sankyo | Regulatory AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure daiichisankyo.com ↗
Daiichi Sankyo, Inc. announced today that the United States Food and Drug Administration (FDA) has approved AZOR(TM) (amlodipine and olmesartan medoxomil) for the treatment of hypertension, also known as high blood pressure. |
| 2007-07-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval Of Amlodipine Besylate Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration (FDA) has granted approval for the company's ANDA for Amlodipine Besylate Tablets, 2.5 mg, 5 mg and 10 mg. |
| 2007-05-22 | Daiichi Sankyo | Results Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007) First Release of Data for New Combination daiichisankyo.com ↗
Combining the calcium channel blocker amlodipine besylate with the angiotensin receptor blocker olmesartan medoxomil, produced significant mean reductions in seated systolic and diastolic blood pressure in patients with hypertension, according to data presented at the American Society of Hypertension¨s Twenty-Second Annual Scientific Meeting at Exposition (ASH 2007). |
| 2007-05-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Provides Update On Generic Lotrel ® tevapharm.com ↗
the U. S. Food and Drug Administration granted to Teva final approval of its amlodipine besylate/ benazepril products |
| 2006-11-29 | Daiichi Sankyo | Regulatory DAIICHI SANKYO, INC. ANNOUNCES FILING OF NEW DRUG APPLICATION FOR AMLODIPINE BESYLATE / OLMESARTAN MEDOXOMIL COMBINATION FOR THE TREATMENT OF HYPERTENSION daiichisankyo.com ↗
Daiichi Sankyo, Inc. announced today that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for a fixed dose combination of two antihypertensives, the calcium channel blocker (CCB) amlodipine besylate (currently marketed by Pfizer as Norvasc®) and the angiotensin receptor blocker (ARB) olmesartan medoxomil, or BENICAR®. |
| 2006-06-29 | Perrigo Company | Regulatory Perrigo Company to Market Amlodipine Besylate Tablets perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, Kali Laboratories, Inc., a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), has received tentative approval from the U.S. Food and Drug Administration (FDA) on its ANDA for Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base). |
| 2005-03-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval Of Amlodipine Besylate Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Amlodipine Besylate Tablets, 2.5 mg, 5 mg and 10 mg. |
All press releases naming this drug 49 releases
Evidence & citations 58 cited values
Every value below carries the sentence it was read from. 561 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amlodipine | “The purpose of this study is to assess the pharmacokinetic characteristics of olmesartan and S-amlodipine after single oral administration of Sevikar tab. 10/40mg, a...” NCT02955498 ↗537“The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged,...” NCT04040634 ↗ “Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC)...” NCT06275763 ↗ “The antihypertensive effect of the increased dose of angiotensin II receptor blocker (AII antagonist) is compared with that of the additional combined use of amlodipine in...” NCT00144144 ↗ “The dosages were SPC1001 High (4/2.5/1.25 mg), SPC1001 Mid1 (2.67/1.67/0.83 mg), SPC1001 Mid2 (4/1.25/1.25 mg), SPC1001 Low (2/1.25/0.625 mg), SPC3001 (candesartan 8 mg),...” PMID 41162308 ↗ Oct 2025 “The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment...” NCT01190007 ↗ “We investigated the blood pressure (BP) lowering efficacy of two dual antihypertensive therapies, the amlodipine/benazepril and benazepril/hydrochlorothiazide combinations,...” PMID 41053442 ↗ Oct 2025 “Patients whose blood pressure (BP) remained uncontrolled were randomized double-blind to fixed-dose losartan 50 mg/hydrochlorothiazide 12.5 mg/amlodipine 5 mg (L50/H12.5/A5) or...” PMID 25271811 ↗ Oct 2014 “Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using...” NCT02966717 ↗ “The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single-pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in...” PMID 39504016 ↗ Nov 2024 “To evaluate the efficacy and safety of amlodipine besylate and candesartan cilexetil administered in a fixed-dose combination tablet versus co-administered as their separate...” NCT03231982 ↗ |
| Known as | ALD | “fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV) as study group” PMID 36451242 ↗ Dec 2022 |
| Known as | Aml | “The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the...” PMID 28734660 ↗ Jul 201711“OBJECTIVE: The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a...” PMID 20678674 ↗ Jul 2010 “OBJECTIVE: To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ)...” PMID 23721363 ↗ Jul 2013 “This study aimed to assess the efficacy and safety of a combination therapy of Allisartan Isoproxil 240 mg and Amlodipine 5 mg (ALI/AML) compared to AML 5 mg monotherapy in...” PMID 39821945 ↗ Jan 2025 “Central blood pressure (BP), an important measure of cardiovascular risk, has been shown to be effectively reduced by calcium channel blockade with amlodipine (AML) plus...” PMID 24293132 ↗ Nov 2013 “This study aimed to evaluate the long-term safety and efficacy of a triple combination therapy with 20 mg azilsartan (AZL), 5 mg amlodipine (AML) and 12.5 mg hydrochlorothiazide (HCTZ).” PMID 29235365 ↗ Dec 2017 “Therefore, we sought to identify predictors of significant hsCRP reduction after the use of rosuvastatin (RSV)/amlodipine (AML) and atorvastatin (ATV)/AML.” PMID 40429358 ↗ May 2025 “Both Olmesartan (OLM)/Amlodipine (AML) combination and Hydrochlorothiazide (HCTZ) have proven to be efficacious and safe in lowering blood pressure” NCT00902538 ↗ “Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet.” NCT01838850 ↗ “This study aimed to evaluate the efficacy and tolerability of irbesartan (IRB) and amlodipine (AML) combination therapy” PMID 38704294 ↗ May 2024 “amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm” PMID 23254596 ↗ Dec 2012 |
| Known as | Amlo | “triple-combination of olmesartan/amlodipine/rosuvastatin (Olme/Amlo/Rosu)” PMID 37814541 ↗ Jan 2023 |
| Known as | Amlodin | “compared with those of amlodipine besilate (Norvasc or Amlodin)” NCT00294567 ↗ |
| Known as | Amlodipine (AM) | “Amlodipine (AM)” NCT01614366 ↗ |
| Known as | Amlodipine (as besilate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine and Hydrocholorothiazide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00656331 ↗ |
| Known as | Amlodipine benzenesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | amlodipine besilate | “Study to determine the potential pharmacokinetic interaction of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate and amlodipine as amlodipine besilate at...” NCT04245046 ↗2“compared with those of amlodipine besilate (Norvasc or Amlodin)” NCT00294567 ↗ “amlodipine as amlodipine besilate” NCT04262765 ↗ |
| Known as | Amlodipine Besylate | “The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the...” PMID 28734660 ↗ Jul 201720“OBJECTIVE: The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a...” PMID 20678674 ↗ Jul 2010 “This study is being performed to determine the bioavailability, or extent of absorption into the body, of a 10 mg amlodipine besylate orally disintegrating tablet (ODT) as...” NCT01138826 ↗ “The objective of this study is to compare the rate and extent of absorption of amlodipine from a test formulation of Amlodipine Besylate Tablets, 10 mg versus the reference...” NCT00841815 ↗ “Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion” NCT00407537 ↗ “Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once” NCT02739672 ↗ “Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9%” NCT05667818 ↗ “For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy.” NCT03015311 ↗ “the calcium channel blocker amlodipine besylate and the nonsteroidal anti-inflammatory drug (NSAID) celecoxib” NCT02172040 ↗ “Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.” NCT00170950 ↗ “A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg” NCT01823913 ↗ |
| Known as | Amlodipine besylate component of amlessa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of amturnide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of azor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of caduet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of consensi | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of copalia | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of dafiro amlodipine besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of dafiro-hct amlodipine besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of exforge | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of exforge amlodipine besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of exforge hct | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of exforge-hct amlodipine besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of imprida amlodipine besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of imprida-hct amlodipine besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of lotrel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of onduarp | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of prestalia | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of tekamlo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of tribenzor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine besylate component of twynsta | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlodipine Besylate Tablets | “High-resistance type: Amlodipine Besylate Tablets 5mg, once daily, orally.” NCT07240909 ↗ |
| Known as | amlodipine camsylate | “This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with...” NCT01830517 ↗1“amlodipine camsylate 5mg + losartan potassium 100mg treatment (A/L 5/100) group” PMID 29150250 ↗ Nov 2017 |
| Known as | AMLODIPINE COMPONENT OF CKD-330 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | AMLODIPINE MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | amlodipine orotate | “A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg” NCT01823913 ↗ |
| Known as | Amlodipine Pfizer 10mg (Pfizer) | “Amlodipine Pfizer 10mg (Pfizer)” NCT03106597 ↗ |
| Known as | Amlodipino | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amlor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Amodipin | “This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with...” NCT01830517 ↗ |
| Known as | Amvaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Antacal | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Astudal 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | HGP0904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243319 ↗ |
| Known as | Istin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Lodipressin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Monopina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Norliqva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | Norvas | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | NorvasC | “The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks.” NCT01996449 ↗14“Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension” NCT00281580 ↗ “Norvasc®(Amlodipine Besylate) Tablets, 5mg of Pfizer Laboratories Div. Pfizer Inc.” NCT05667818 ↗ “Study drugs: amlodipine (Norvasc®) and nifedipine GITS (Adalat®)” NCT01030081 ↗ “compared with those of amlodipine besilate (Norvasc or Amlodin)” NCT00294567 ↗ “Step 4 - Addition of Norvasc 2.5-10 mg po od.” NCT00438113 ↗ “amlodipine therapy (NORVASC 10 mg/day)” NCT03054467 ↗ “Norvasc (amlodipine) 5mg, 1 tablet/day” NCT05288400 ↗ “Drug: Amlodipine (Norvasc)” NCT01518855 ↗ “Amlodipine 5mg(Norvasc)” NCT04081844 ↗ “amlodipine (Norvasc)” NCT01922687 ↗ |
| Known as | NSC-758922 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | SPC4001 | “The dosages were SPC1001 High (4/2.5/1.25 mg), SPC1001 Mid1 (2.67/1.67/0.83 mg), SPC1001 Mid2 (4/1.25/1.25 mg), SPC1001 Low (2/1.25/0.625 mg), SPC3001 (candesartan 8 mg),...” PMID 41162308 ↗ Oct 2025 |
| Known as | SPC4002 | “The dosages were SPC1001 High (4/2.5/1.25 mg), SPC1001 Mid1 (2.67/1.67/0.83 mg), SPC1001 Mid2 (4/1.25/1.25 mg), SPC1001 Low (2/1.25/0.625 mg), SPC3001 (candesartan 8 mg),...” PMID 41162308 ↗ Oct 2025 |
| Known as | UK-48,340-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Known as | UK-48,340-26 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1491 ↗ |
| Action | Inhibit | “amlodipine, a calcium channel blocker” PMID 24842697 ↗ Jul 2014 |
| Modality | Other / unclassified | “the use of a calcium channel blocker (amlodipine)” NCT04954196 ↗ |
| Route | Oral | “amlodipine po qd” NCT00156403 ↗ |